Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | MET | P08581 | 6/20 | 0.38 |
| ▸ | ABCC9 | O60706 | 11/20 | 0.37 |
| ▸ | KCNJ11 | Q14654 | 11/20 | 0.37 |
| ▸ | ABCC8 | Q09428 | 7/20 | 0.37 |
| ▸ | KCNJ8 | Q15842 | 7/20 | 0.37 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL561558 | 0.90 | MET (0.46) | KDM4EALDH1A1MAPTMETABCC9 | |
| SCHEMBL561540 | 0.85 | MET (0.48) | METABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL10212503 | 0.84 | MET (0.43) | KDM4EALDH1A1MAPTRECQLMET | |
| SCHEMBL561326 | 0.82 | TUBB4A (0.43) | KDM4EALDH1A1MAPTMETABCC9 | |
| SCHEMBL562365 | 0.82 | MET (0.49) | KDM4EALDH1A1METABCC9KCNJ11 | |
| SCHEMBL562277 | 0.82 | MET (0.41) | KDM4EALDH1A1MAPTMETABCC9 | |
| SCHEMBL561769 | 0.82 | KDM4E (0.37) | KDM4EALDH1A1MAPTMETABCC9 | |
| SCHEMBL562100 | 0.81 | ABCC9 (0.39) | KDM4EALDH1A1MAPTABCC9KCNJ11 | |
| SCHEMBL561361 | 0.81 | MET (0.40) | METABCC9KCNJ11ABCC8KCNJ8 | |
| SCHEMBL562201 | 0.80 | MET (0.44) | KDM4EALDH1A1METABCC9KCNJ11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| US-8759341-B2 | Bi- and tricyclic indazole-substituted 1,4-dihydropyridine derivatives and uses thereof | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2014-06-24 | — | — | US | disclosed |
| EP-2398790-B1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER IP GMBH (DE) | 2013-07-03 | — | — | EP | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2012-02-09 | — | — | US | disclosed |
| WO-2010094405-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035409-A1 | BI- AND TRICYCLIC INDAZOLE-SUBSTITUTED 1,4-DIHYDROPYRIDINE DERIVATIVES AND USES THEREOF | MET, RET, ERBB2 | KDM4E 1206/4885ALDH1A1 916/4885MAPT 1788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.